Nurix Therapeutics (NASDAQ:NRIX – Get Rating) issued its quarterly earnings data on Thursday. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.02), Fidelity Earnings reports. Nurix Therapeutics had a negative return on equity of 45.28% and a negative net margin of 399.14%.

NRIX stock opened at $17.71 on Friday. The company's 50-day moving average price is $10.99 and its 200 day moving average price is $15.41. Nurix Therapeutics has a 52 week low of $7.52 and a 52 week high of $37.42.

Get Nurix Therapeutics alerts:

Institutional investors and hedge funds have recently made changes to their positions in the business. Dimensional Fund Advisors LP raised its position in Nurix Therapeutics by 104.1% during the first quarter. Dimensional Fund Advisors LP now owns 237,525 shares of the company's stock worth $3,328,000 after acquiring an additional 121,167 shares during the last quarter. UBS Group AG raised its position in Nurix Therapeutics by 49.7% during the first quarter. UBS Group AG now owns 148,704 shares of the company's stock worth $2,083,000 after acquiring an additional 49,367 shares during the last quarter. Alyeska Investment Group L.P. raised its position in Nurix Therapeutics by 5.0% during the first quarter. Alyeska Investment Group L.P. now owns 120,750 shares of the company's stock worth $1,692,000 after acquiring an additional 5,750 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Nurix Therapeutics by 34.1% in the first quarter. JPMorgan Chase & Co. now owns 120,516 shares of the company's stock valued at $1,688,000 after buying an additional 30,664 shares during the last quarter. Finally, Ensign Peak Advisors Inc raised its position in shares of Nurix Therapeutics by 1,634.1% in the first quarter. Ensign Peak Advisors Inc now owns 84,797 shares of the company's stock valued at $1,188,000 after buying an additional 79,907 shares during the last quarter. Institutional investors own 89.94% of the company's stock.

Several brokerages have issued reports on NRIX. Royal Bank of Canada lowered their price objective on shares of Nurix Therapeutics from $42.00 to $39.00 and set an "outperform" rating on the stock in a research report on Monday, April 18th. Wells Fargo & Company raised shares of Nurix Therapeutics from an "equal weight" rating to an "overweight" rating and set a $25.00 target price on the stock in a report on Tuesday, May 31st. Stifel Nicolaus lowered their target price on shares of Nurix Therapeutics from $44.00 to $37.00 in a report on Friday. HC Wainwright lowered their target price on shares of Nurix Therapeutics from $62.00 to $60.00 and set a "buy" rating on the stock in a report on Thursday, April 14th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Nurix Therapeutics from $46.00 to $37.00 and set an "overweight" rating on the stock in a report on Friday. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $40.78.

About Nurix Therapeutics (Get Rating)

Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

Featured Articles

• Get a free copy of the StockNews.com research report on Nurix Therapeutics (NRIX)
• MarketBeat: Week in Review 7/4 – 7/8
• Levi Strauss Proves Resilient For Dividend Investors
• AT&T (NYSE:T) Is Its Cheaper Valuation Worth A Buy?
• Altria Group (NYSE MO): A Contentious High-Yield Dividend Stock
• 3 Grocery Stocks That Can Help Take a Bite Out of Inflation

Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.